Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
Hosted on MSN23h
NHS England to offer Casgevy for sickle cell disease patients
Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.